Patient Safety and Unapproved Stem Cell Products
Unapproved does not mean untested in theory — it means untested to FDA standards. The FDA has documented serious harm from products administered outside its approval framework.
Categories of documented harm
Infections
The FDA and CDC have investigated outbreaks in which patients developed bacterial bloodstream infections, joint infections, and epidural abscesses after receiving umbilical cord blood-derived products at multiple clinics. Some patients required hospitalization and prolonged antibiotic treatment.
Vision loss
The FDA has publicly reported cases of severe, permanent vision loss in patients who received intravitreal injections of adipose-derived cells marketed as a treatment for macular degeneration. Some patients were left legally blind.
Tumor formation
Case reports in the medical literature describe tumor-like masses developing at injection sites months to years after unregulated stem cell administration. The clonal proliferation potential of stem cells is one reason careful manufacturing controls and long-term follow-up are required for approved products.
Cardiovascular and other systemic events
Adverse events reported after intravenous administration of unapproved stem cell products include pulmonary emboli, strokes, and severe allergic reactions.
Why unapproved products carry these risks
- Manufacturing is not held to cGMP standards, so contamination risk is higher.
- Product identity and cell count are not consistently verified batch to batch.
- Long-term safety data does not exist because there is no systematic follow-up.
- Routes of administration (intravenous, intrathecal, intra-articular, intraocular) may not match how the source tissue was ever intended to behave.
If you or someone you know has had a problem
Patients and providers can report adverse events to the FDA through the MedWatch program at FDA MedWatch. Reporting helps the agency identify patterns and take action against manufacturers or clinics causing harm.